Grufity logo
Grufity logo

Latest Paradigm Biocapital Advisors LP Stock Portfolio

$5.34Billion | No. of Holdings #28

Paradigm Biocapital Advisors LP Performance

2026 Q2+21.97%
YTD+35.97%
2025+33.45%

About Paradigm Biocapital Advisors LP and 13F Hedge Fund Stock Holdings

On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Paradigm Biocapital Advisors LP reported an equity portfolio of $5.3 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Paradigm Biocapital Advisors LP are RVMD, NUVL, EWTX. The fund has invested 22.3% of it's portfolio in REVOLUTION MEDICINES INC and 13.7% of portfolio in NUVALENT INC. <br><br> The fund managers got completely rid off ARCELLX INC (ACLX), CENTESSA PHARMACEUTICALS PLC (CNTA) and TERNS PHARMACEUTICALS INC (TERN) stocks. They significantly reduced their stock positions in VAXCYTE INC (PCVX), LEXEO THERAPEUTICS INC and TYRA BIOSCIENCES INC (TYRA). Paradigm Biocapital Advisors LP opened new stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), MBX BIOSCIENCES INC and JADE BIOSCIENCES INC (AVTE). The fund showed a lot of confidence in some stocks as they added substantially to ASSEMBLY BIOSCIENCES INC (ASMB), VIRIDIAN THERAPEUTICS INC (VRDN) and SPYRE THERAPEUTICS INC (AGLE).
Paradigm Biocapital Advisors LP Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$5.34Billion
  as of Aug 14, 2026

Paradigm Biocapital Advisors LP Annual Return Estimates Vs S&P 500

Our best estimate is that Paradigm Biocapital Advisors LP made a return of 21.97% in the last quarter. In trailing 12 months, it's portfolio return was 114.23%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
alnylam pharmaceuticals inc144,494,000
mbx biosciences inc138,442,000
jade biosciences inc63,491,500
achieve life science inc32,335,600
maplight therapeutics inc24,580,900
kardigan inc21,465,000
editas medicine inc18,100,700
New stocks bought by Paradigm Biocapital Advisors LP

Additions

Ticker% Inc.
assembly biosciences inc133
viridian therapeutics inc113
spyre therapeutics inc96.23
genmab a/s64.83
tango therapeutics inc58.55
edgewise therapeutics inc38.7
apogee therapeutics inc16.92
nuvalent inc11.27
Additions to existing portfolio by Paradigm Biocapital Advisors LP

Reductions

Ticker% Reduced
vaxcyte inc-55.61
lexeo therapeutics inc-32.48
tyra biosciences inc-11.02
erasca inc-8.11
eyepoint inc-8.02
oruka therapeutics inc-7.58
revolution medicines inc-4.42
Paradigm Biocapital Advisors LP reduced stake in above stock

Sold off

Ticker$ Sold
arcellx inc -662,973,000
centessa pharmaceuticals plc-141,961,000
maze therapeutics inc -81,920,300
terns pharmaceuticals inc -116,854,000
urogen pharma ltd -30,637,000
oric pharmaceuticals inc -21,554,400
cytokinetics inc -97,603,300
scholar rock hldg corp -60,274,100
Paradigm Biocapital Advisors LP got rid off the above stocks

Sector Distribution

Paradigm Biocapital Advisors LP has about 77.8% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare77.8
Others22.2

Market Cap. Distribution

Paradigm Biocapital Advisors LP has about 27.7% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • LARGE-CAP
  • UNALLOCATED
  • SMALL-CAP
Category%
MID-CAP42.8
LARGE-CAP27.7
UNALLOCATED22.2
SMALL-CAP7.1

Stocks belong to which Index?

About 67.4% of the stocks held by Paradigm Biocapital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200067.4
Others32.6
Top 5 Winners (%)%
RVMD
revolution medicines inc
90.5 %
oruka therapeutics inc
90.5 %
apogee therapeutics inc
51.4 %
AGLE
spyre therapeutics inc
48.4 %
TNGX
tango therapeutics inc
36.9 %
Top 5 Winners ($)$
RVMD
revolution medicines inc
586.0 M
NUVL
nuvalent inc
118.4 M
AGLE
spyre therapeutics inc
111.1 M
oruka therapeutics inc
103.0 M
EWTX
edgewise therapeutics inc
80.3 M
Top 5 Losers (%)%
INSM
insmed inc
-34.2 %
IVA
inventiva sa
-31.9 %
lexeo therapeutics inc
-15.8 %
TYRA
tyra biosciences inc
-15.7 %
OLMA
olema pharmaceuticals inc
-15.6 %
Top 5 Losers ($)$
INSM
insmed inc
-73.4 M
OLMA
olema pharmaceuticals inc
-20.0 M
TARS
tarsus pharmaceuticals inc
-19.2 M
TYRA
tyra biosciences inc
-12.3 M
IVA
inventiva sa
-7.1 M

Paradigm Biocapital Advisors LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP has 28 stocks in it's portfolio. About 75.2% of the portfolio is in top 10 stocks. INSM proved to be the most loss making stock for the portfolio. RVMD was the most profitable stock for Paradigm Biocapital Advisors LP last quarter.

$5.34BTotal Value
42.00Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Paradigm Biocapital Advisors LP, last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
Paradigm Biocapital Advisors LP's holding in Belite Bio Inc over time
3.56%1,232,880
$189.84M
3.56%
increased 10.59 percentadded
GMAB
Genmab A/S

Genmab A/S

GMAB
Paradigm Biocapital Advisors LP's holding in Genmab A/S over time
6.76%13,133,100
$360.77M
6.76%
increased 64.83 percentadded
IVA
Inventiva Sa

Inventiva Sa

IVA
Paradigm Biocapital Advisors LP's holding in Inventiva Sa over time
0.28%4,000,000
$15.12M
0.28%
unchanged 0 percentunchanged